Browse our 650+ Publications​

Latest Publications

Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children

Whangbo et al.
Blood Advances
September 2019
Authors and Affiliates
Whangbo JS1,2,3, Kim HT4,5, Mirkovic N6, Leonard L1,2, Poryanda S6, Silverstein S1,2, Kim S6, Reynolds CG6, Rai SC6, Verrill K1,2, Lee MA1,2,3, Margossian S1,2,3, Duncan C1,2,3, Lehmann L1,2,3, Huang J3,7, Nikiforow S3,6, Alyea EP 3rd3,6, Armand P3,6, Cutler CS3,6, Ho VT3,6, Blazar BR8, Antin JH3,6, Soiffer RJ3,6, Ritz J3,6, Koreth J3,6.; 1 Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA. 2 Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston MA. 3 Harvard Medical School, Boston, MA. 4 Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA. 5 Harvard School of Public Health, Boston, MA. 6 Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA. 7 Dermatology Program, Division of Immunology, Boston Children's Hospital, Boston, MA; and. 8 Masonic Cancer Center and Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN.

Deep generative models for T cell receptor protein sequences

Davidsen et al.
eLIFE
September 2019
Authors and Affiliates
Davidsen K1,2, Olson BJ1,2, DeWitt WS 3rd1,2, Feng J1,2, Harkins E1,2, Bradley P1,2, Matsen FA 4th1,2.; 1 University of Washington, Seattle, United States. 2 Fred Hutchinson Cancer Research Center, Seattle, United States.

Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer

Kudo et al.
Annals of Oncology
September 2019
Authors and Affiliates
Kudo Y1,2, Haymaker C1, Zhang J3, Reuben A4, Duose DY1, Fujimoto J1, Roy-Chowdhuri S5, Solis Soto LM1, Dejima H1, Parra ER1, Mino B1, Abraham R1, Ikeda N2, Vaporcyan A6, Gibbons D4, Zhang J4, Lang FF7, Luthra R1,8, Lee JJ3, Moran C5, Huse JT1,5, Kadara H1, Wistuba II1,4.; 1 Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA. 2 Department of Surgery, Tokyo Medical University, Tokyo, Japan. 3 Departments of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA. 4 Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. 5 Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA. 6 Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA. 7 Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, USA. 8 Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, USA.

Clonal replacement of tumor-specific T cells following PD-1 blockade

Yost et al.
Nature Medicine
August 2019
Authors and Affiliates
Yost KE1, Satpathy AT2,3,4, Wells DK5, Qi Y1, Wang C6, Kageyama R5, McNamara KL7,8,9, Granja JM1,8,10, Sarin KY11, Brown RA12,11, Gupta RK13, Curtis C7,8,9, Bucktrout SL5, Davis MM5,14,15,16, Chang ALS17, Chang HY18,19,20,21,22; 1 Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA. 2 Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA. satpathy@stanford.edu. 3 Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. satpathy@stanford.edu. 4 Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. satpathy@stanford.edu. 5 Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. 6 iRepertoire Inc, Huntsville, AL, USA. 7 Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA. 8 Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. 9 Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. 10 Program in Biophysics, Stanford University School of Medicine, Stanford, CA, USA. 11 Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA. 12 Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. 13 Stanford Biobank, Stanford University School of Medicine, Palo Alto, CA, USA. 14 Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA. 15 Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA. 16 Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA. 17 Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA. alschang@stanford.edu. 18 Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA. howchang@stanford.edu. 19 Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. howchang@stanford.edu. 20 Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. howchang@stanford.edu. 21 Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA. howchang@stanford.edu. 22 Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA, USA. howchang@stanford.edu.

Effector TH17 Cells Give Rise to Long-Lived TRM Cells that Are Essential for an Immediate Response against Bacterial Infection

Vesely et al.
Cell
August 2019
Authors and Affiliates
Amezcua Vesely MC1, Pallis P2, Bielecki P2, Low JS2, Zhao J3, Harman CCD1, Kroehling L2, Jackson R2, Bailis W2, Licona-Limón P4, Xu H2, Iijima N2, Pillai PS5, Kaplan DH6, Weaver CT7, Kluger Y8, Kowalczyk MS9, Iwasaki A1, Pereira JP2, Esplugues E10, Gagliani N11, Flavell RA12.; 1 Department of Immunobiology, School of Medicine, Yale University, New Haven, CT, USA; Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT, USA. 2 Department of Immunobiology, School of Medicine, Yale University, New Haven, CT, USA. 3 Department of Immunobiology, School of Medicine, Yale University, New Haven, CT, USA; Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA; Program of Computational Biology and Bioinformatics, Yale University, New Haven, CT 06520, USA. 4 Departamento de Biología Celular y del Desarrollo, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Ciudad de México, México. 5 Department of Immunobiology, School of Medicine, Yale University, New Haven, CT, USA; Koch Institute for Integrative Cancer Research and Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA. 6 Department of Dermatology and Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA. 7 Departments of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. 8 Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA; Program of Computational Biology and Bioinformatics, Yale University, New Haven, CT 06520, USA; Applied Mathematics Program, Yale University, New Haven, CT 06511, USA. 9 Broad Institute of MIT and Harvard, Cambridge, MA, USA. 10 Department of Immunobiology, School of Medicine, Yale University, New Haven, CT, USA; Laboratory of Molecular and Cellular Immunology, Principe Felipe Research Center (CIPF), 46012 Valencia, Spain. 11 Department of Immunobiology, School of Medicine, Yale University, New Haven, CT, USA; I. Medical Department and Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf 20246 Hamburg, Germany; Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institute, 17176 Stockholm, Sweden. Electronic address: n.gagliani@uke.de. 12 Department of Immunobiology, School of Medicine, Yale University, New Haven, CT, USA; Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT, USA. Electronic address: richard.flavell@yale.edu

The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients

Khunger et al.
OncoImmunology
August 2019
Authors and Affiliates
Khunger A1, Rytlewski JA2, Fields P2, Yusko EC2, Tarhini AA3; 1 Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA. 2 Adaptive Biotechnologies, Seattle, WA, USA. 3 Department of Cutaneous Oncology, Moffitt Comprehensive Cancer Center, Tampa, Florida, USA.

A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer.

Ross et al.
Prostate Cancer and Prostatic Diseases
August 2019
Authors and Affiliates
Ross AE1, Hurley PJ2,3,4, Tran PT4,5,6, Rowe SP6, Benzon B2, Neal TO3,4, Chapman C3,4, Harb R3,4, Milman Y3,4, Trock BJ2,3,4, Drake CG7, Antonarakis ES2,3,4; 1 Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA. ashley.ross@usoncology.com. 2 Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA. 3 The Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 4 The Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA. 5 The Department of Radiation Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 6 The Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA. 7 The Department of Medicine, Columbia University, New York, NY, USA.

Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy

Shah et al.
Blood Advances
August 2019
Authors and Affiliates
Nirali N. Shah,1,* Haiying Qin,1,* Bonnie Yates,1 Ling Su,2 Haneen Shalabi,1 Mark Raffeld,3 Mark A. Ahlman,4 Maryalice Stetler-Stevenson,5 Constance Yuan,5 Shuang Guo,2 Siyuan Liu,2 Stephen H. Hughes,6 Terry J. Fry,1,7,8,† and Xiaolin Wu2,†; 1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD; 2Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD; 3Molecular Diagnostics Section, Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, MD; 4Radiology and Imaging Sciences, NIH Clinical Center, Bethesda, MD; 5Flow Cytometry, Department of Pathology, NCI, NIH, Bethesda, MD; 6HIV Dynamics and Replication Program, NCI, NIH, Frederick, MD; 7Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO; and 8Center for Cancer and Blood Disorders, Children’s Hospital Colorado, Aurora, CO

Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients

Abraham et al.
Blood Advances
July 2019
Authors and Affiliates
Allistair A. Abraham,1,* Tami D. John,2,3,* Michael D. Keller,1 C. Russell N. Cruz,1 Baheyeldin Salem,1 Lauren Roesch,1 Hao Liu,4 Fahmida Hoq,1 Bambi J. Grilley,2,3 Adrian P. Gee,2,3 Hema Dave,1 David A. Jacobsohn,1 Robert A. Krance,2,3 Elizabeth. J. Shpall,2,3 Caridad A. Martinez,2,3 Patrick J. Hanley,1,† and Catherine M. Bollard1,† 1Center for Cancer and Immunology Research, Children’s National Health System and Department of Pediatrics, The George Washington University, Washington, DC; 2Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Houston, TX; 3Texas Children’s Hospital, Houston, TX; and 4Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN
Previous Next